Analysts Set The Chemours Company (NYSE:CC) Target Price at $24.88

Shares of The Chemours Company (NYSE:CC - Get Free Report) have been assigned a consensus rating of "Hold" from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $24.88.

CC has been the topic of several recent research reports. Royal Bank of Canada reissued an "outperform" rating and set a $25.00 price target on shares of Chemours in a research report on Thursday, December 12th. Barclays boosted their target price on shares of Chemours from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. The Goldman Sachs Group lowered their price target on shares of Chemours from $29.00 to $23.00 and set a "neutral" rating for the company in a report on Tuesday, September 3rd. BMO Capital Markets lifted their price target on shares of Chemours from $30.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, October 7th. Finally, Morgan Stanley decreased their price objective on shares of Chemours from $30.00 to $25.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 5th.

Insider Transactions at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. This trade represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.47% of the company's stock.

Institutional Trading of Chemours

A number of institutional investors and hedge funds have recently modified their holdings of CC. Appian Way Asset Management LP acquired a new stake in shares of Chemours during the 3rd quarter worth approximately $34,151,000. Vision One Management Partners LP bought a new position in Chemours during the 3rd quarter worth $28,252,000. Marshall Wace LLP increased its position in Chemours by 23.8% in the second quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company's stock worth $158,213,000 after buying an additional 1,347,710 shares during the period. Khrom Capital Management LLC lifted its stake in Chemours by 54.6% in the second quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company's stock valued at $78,016,000 after buying an additional 1,220,967 shares during the last quarter. Finally, Scopia Capital Management LP acquired a new position in shares of Chemours during the third quarter valued at $13,623,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Trading Down 1.8 %

NYSE CC traded down $0.32 during mid-day trading on Friday, hitting $17.01. The company's stock had a trading volume of 1,348,825 shares, compared to its average volume of 1,595,171. The firm has a market capitalization of $2.54 billion, a P/E ratio of 34.02 and a beta of 1.80. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. Chemours has a 52-week low of $15.10 and a 52-week high of $32.70. The stock's fifty day simple moving average is $19.49 and its two-hundred day simple moving average is $20.34.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating analysts' consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. During the same quarter last year, the firm posted $0.64 EPS. The business's revenue for the quarter was up .9% compared to the same quarter last year. Research analysts expect that Chemours will post 1.35 EPS for the current year.

Chemours Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were given a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 5.88%. The ex-dividend date of this dividend was Friday, November 15th. Chemours's payout ratio is currently 200.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.